I don't think the nuke IP was the impetus for the buyout. MRK right now is running a trial of sofo combined with their next gen PI and NS5A. So apparently they feel their in house combo needs an assist from a 3rd drug, ideally a nuke, to be more competitive - and my guess is the deep dive was in IDIX's nuke candidates that they feel they can perhaps move along quickly into combination trials in the clinic. they are looking at regimens as short as 4 weeks with the triple combo if memory serves. the trial can be found at the clicaltrials.gov site
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.